March 18, 2018 12:31 PM ET


Company Overview of Proteostasis Therapeutics, Inc.

Company Overview

Proteostasis Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics that treat diseases caused by dysfunctional protein processing, such as cystic fibrosis. Its lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class that is in Phase-I studies. The company is also developing PTI-801, a corrector molecule; PTI-808, a potentiator molecule; and unfolded protein response (UPR) modulators that are in preclinical development. It has collaboration with Astellas Pharma, Inc. to research and identify therapies targeting the Unfolded Protein Response...

200 Technology Square

4th Floor

Cambridge, MA 02139

United States

Founded in 2006



Key Executives for Proteostasis Therapeutics, Inc.

President, Chief Executive Officer & Director
Age: 45
Total Annual Compensation: $682.6K
Executive VP & Chief Medical Officer
Age: 48
Total Annual Compensation: $453.9K
Compensation as of Fiscal Year 2016.

Proteostasis Therapeutics, Inc. Key Developments

Proteostasis Therapeutics, Inc. Promotes Marija (Masha) Zecevic as Chief Operating Officer

On February 1, 2018, the Board of Directors of Proteostasis Therapeutics, Inc. elected Marija (Masha) Zecevic, PhD., current Chief Business Officer, as the Company's Chief Operating Officer. Dr. Zecevic, age 44, has been serving as Chief Operating Officer since February 2018 and was Chief Business Officer from March 2017 to February 2018.

Proteostasis Therapeutics, Inc. Presents at Leerink Partners 7th Annual Global Healthcare Conference, Feb-15-2018 01:30 PM

Proteostasis Therapeutics, Inc. Presents at Leerink Partners 7th Annual Global Healthcare Conference, Feb-15-2018 01:30 PM. Venue: The Lotte New York Palace, New York, New York, United States. Speakers: Meenu Chhabra, President, Chief Executive Officer & Director.

Proteostasis Therapeutics, Inc Announces Principal Accounting Officer Changes

Proteostasis Therapeutics, Inc. announced that On December 5, 2017, Brett Hagen, VP, Finance and Principal Accounting Officer provided notice of his resignation from the company, effective December 31, 2017, for personal reasons. On December 7, 2017, the Board of Directors of the company elected Helen M. Boudreau, the company’s Chief Financial Officer and Treasurer, as the company’s Principal Accounting Officer. Ms. Boudreau has been Chief Financial Officer and Treasurer since July 2017. Ms. Boudreau served on company Board of Directors from February 2016 to July 2017. Prior to joining the company, Ms. Boudreau served as the Chief Financial Officer of FORMA Therapeutics, Inc. from 2014 to 2017.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Proteostasis Therapeutics, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at